Synch is proud to have acted as legal advisor to AlzeCure Pharma AB (“AlzeCure”), a pharmaceutical company developing innovative drug candidates for diseases affecting the nervous system, including Alzheimer’s disease and pain, in connection with its recently completed rights issue.
The rights issue, which closed on July 22, 2025, was oversubscribed by 212 percent. Following this strong demand, AlzeCure’s Board of Directors resolved to fully exercise the SEK 10 million over-allotment option, which was also fully subscribed. In total, the company will receive approximately SEK 58.5 million before issue costs.
Synch is a business-oriented law firm with innovation and technology at its heart. Our mission is to bring calm to any legal question, no matter the challenge. We do this by using our curiosity to deeply understand our clients' challenges and fully grasp their needs, applying a combination of our knowledge, experience, and the best use of technology through advisory services and packaged solutions.
Synch acted as legal advisor to AlzeCure with a team consisting of partner Mattias Anjou, senior associate Olof Hultén, and associate Clara Löfgren, alongside Zonda Partners AB as financial advisor and Corpura Fondkommission AB as joint bookrunner.
